Neuromuscular Disorders: In Vitro

This feed focuses on experimental systems, including cell and tissue-based therapies, as well as genomic and proteomic approaches, used to study neuromuscular disorders in vitro. Discover the latest research on neuromuscular disorders in vitro here.

January 13, 2022
Review

Motor neuron replacement therapy for amyotrophic lateral sclerosis.

Neural Regeneration Research
Bochao LiuPaul Lu
January 13, 2022

Optimization of application-driven development of in vitro neuromuscular junction models.

Tissue Engineering. Part B, Reviews
Julie B StricklandEmilia A Solomon
January 13, 2022

Stride-level analysis of mouse open field behavior using deep-learning-based pose estimation.

Cell Reports
Keith SheppardVivek Kumar
January 12, 2022
Preprint
Open Access

Efficient generation of lower induced Motor Neurons by coupling Ngn2 expression with developmental cues

BioRxiv : the Preprint Server for Biology
Francesco LimoneKevin Eggan
January 12, 2022
Open Access

Edaravone activates the GDNF/RET neurotrophic signaling pathway and protects mRNA-induced motor neurons from iPS cells.

Molecular Neurodegeneration
Qian LiMingyao Ying
January 11, 2022

The Assessment of Major Histocompatibility Complex (MHC) Class-I Expression in Different Neuromuscular Diseases.

Degenerative Neurological and Neuromuscular Disease
Maher KurdiNadeem Shafique Butt
January 8, 2022
Open Access

Deficits Associated With Loss of STIM1 in Purkinje Neurons Including Motor Coordination Can Be Rescued by Loss of Septin 7.

Frontiers in Cell and Developmental Biology
Sreeja Kumari Dhanya, Gaiti Hasan
January 8, 2022
Review

Human stem cell models of neurodegeneration: From basic science of amyotrophic lateral sclerosis to clinical translation.

Cell Stem Cell
Elisa GiacomelliLorenz Studer
January 7, 2022

Schistosome TRPML channels play a role in neuromuscular activity and tegumental integrity.

Biochimie
Swarna BaisRobert M Greenberg
January 6, 2022
Review

Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders.

Neurological Research and Practice
Sibylle JablonkaMichael Sendtner
January 5, 2022
Preprint
Open Access

In vitro characterization of the full-length human dynein-1 cargo adaptor BicD2

BioRxiv : the Preprint Server for Biology
R. FagiewiczHelgo Schmidt
January 5, 2022

Parathyroid Cell Differentiation from Progenitor Cells and Stem Cells: Development, Molecular Mechanism, Function, and Tissue Engineering.

Advances in Experimental Medicine and Biology
Selinay Şenkal, Ayşegül Doğan
January 3, 2022

Ddx20, an Olig2 binding factor, governs the survival of neural and oligodendrocyte progenitor cells via proper Mdm2 splicing and p53 suppression.

Cell Death and Differentiation
Norihisa BizenHirohide Takebayashi
January 3, 2022

Diaphragmatic dysfunction in neuromuscular disease, an MRI study.

Neuromuscular Disorders : NMD
Laurike HarlaarNadine A M E van der Beek
January 2, 2022
Preprint
Open Access

Post-Translational Tubulin Modifications in Differentiated Human Neural Stem Cells

BioRxiv : the Preprint Server for Biology
V. B. KnightElba E. Serrano
January 1, 2022
Preprint
Open Access

Microglia influence neurofilament deposition in ALS iPSC-derived motor neurons

BioRxiv : the Preprint Server for Biology
R A AllisonAllison D Ebert

Sign up to follow this feed and discover related papers.

Related Feeds

ALS & FTD: TDP-43

TAR DNA-binding protein 43 (TDP-43) is a pathological protein identified in sporadic Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). Here are the latest discoveries pertaining to TDP-43 and these diseases.

ALS: Genetics

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Pathogenic Mechanisms

Amyotrophic Lateral Sclerosis is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS: Phenotypes

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder characterized phenotypically by progressive muscle weakness. Clinical phenotypes of ALS can be classified based on the pattern, level, and area of onset (e.g. bulbar, cervical, lumbar). Here is the latest research investigating phenotypes of ALS.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here is the latest research on ALS and prions.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research in this field.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS) is associated with the death of neurons that control voluntary muscles. This feed followes the latest research into therapies for this progressive neurodegenerative disease.

Adipose Tissue Heterogeneity

Examining the genomics, transcriptomics, proteomics, and metabolomics of adipose tissue at the single cell level will help build a single cell atlas of these tissues, providing insights into how changes in the map underlie health and disease states. Discover the latest research on adipose tissue heterogeneity here.

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

Antisense Oligonucleotide Therapies: ND

Antisense oligonucleotides are synthetic DNA oligomers that hybridize to a target RNA. This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases.

© 2022 Meta ULC. All rights reserved
/feed-previews/neuromuscular-disorders-in-vitro/60d14e6a-e0fd-4e9c-8c49-3abfd322698c